Cytokinetics Inc (CYTK) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Total Assets Chart for Cytokinetics Inc
Cytokinetics Inc (CYTK) total assets for FY2025 were USD 1.4B, a 1.6% change from FY2024. Cytokinetics Inc's total assets grew from USD 61.0M in 2000 to USD 1.4B in 2025 (2233.9% over 25 years). Total assets compound annual growth rate: 5-year CAGR of 21.7%, 10-year CAGR of 28.6%, 20-year CAGR of 14.7%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $8.53B
- Implied Share Price
- $61.35
- Enterprise Value
- $9.26B
- Revenue (TTM)
- $67.67M
- EBITDA
- -$695.36M
- Profit Margin
- 0.00%
- Trailing P/E
- —
- Forward P/E
- 117.65
- Price/Book (MRQ)
- 60.31
- Price/Sales (TTM)
- 126.04
- EV/EBITDA
- -15.82
- EV/Revenue
- 145.20
- Dividend Yield
- —
- Book Value
- $-1.25
- Free Cash Flow (FY2025)
- -$534.82M
- Free Cash Flow Yield
- -6.27%
Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.